|
 |
|
|
|
Clinical
Research Protocols |
Bladder Cancer:
Localized Muscle Invasive Disease
Title |
Purpose |
Rx |
Contact |
|
| 1. Muscle invasive bladder preservation |
Spare the bladder in muscle invasive TCC |
TURB/XRT/Chemo |
Dr. Kaufman
(MGH) |
|
| Metastatic Bladder Cancer |
||||
| 2. Advanced bladder cancer |
Treatment of metastatic TCC in patients who have failed initial Rx |
Novel drug Rx with Alimta |
Dr. Kaufman
(MGH) |
|
Prostate Cancer:
Local Diseases
| 1. Radiation Therapy with or without Casodex in patients failing radical prostatectomy |
To render patients with PT3 and rising PSA disease free |
XRT + Casodex |
Dr. Shipley (MGH) |
| 2. Brachytherapy and external beam radiotherapy for cancer of the prostate |
Combining radiation modalities for increasing cure |
External beam and brachytherapy |
Dr. Zietman (MGH) 617-724-1158 |
| 3. Radiation Therapy vs. Radiation Therapy plus chemotherapy for advanced prostate cancer |
Improve treatment of patients with a high risk of failure who have locally advanced prostate care |
Ablative hormonal therapy + XRT vs. chemotherapy + XRT |
Dr. Smith (MGH) 617-724-5257 Dr. Kaufman (MGH) 617-726-8689 |
| Metastatic Disease |
|||
| 5. Raloxifene/bone loss in men with prostate cancer |
Treat men on ablative hormonal therapy with drugs to prevent bone loss |
Raloxifene vs. placebo |
Dr. Smith (MGH) 617-724-5257 |
| 6. Remifemin for treatment of hot flashes |
Prevent hot flashes for patients on ablative hormonal therapy |
Reminfemin |
Dr. Smith (MGH) 617-724-5257 |
| 7. Effects of hormonal therapy on skeletal muscle |
Determine the effects of hormonal therapy on skeletal muscle |
Muscle measurements |
Dr. Smith (MGH) 617-724-5257 |
| 8. 00-100 Rosiglitazone |
For hormone – naïve prostate cancer with rising PSA |
Rosiglitazone (Phase III) |
Dr. Kaufman (MGH) 617-726-8689 Dr. Smith (MGH) 617-724-5257 |
| 9. Chemotherapy for hormone refractory prostate cancer: Phase I |
Evaluate toxicity of multiple drug Rx in hormone refractory prostate cancer |
Estramustine, Taxotere, Carboplatin |
Dr. Oh (DFCI) 617-632-3466 |
| 10. Trilostane for androgen independent prostate cancer: Phase II |
Treat hormone refractory metastatic prostate cancer |
Trilostane |
Dr. Smith (MGH) 617-724-5257 Dr. Kaufman (MGH) 617-726-8689 |
Kidney Cancer:
Local Disease
|
1. Non operative treatment of renal cell carcinoma |
Use radiofrequency ablation to treat 4 cm or less peripheral renal cell carcinoma in patients who are not good operative risks |
Radiofrequency ablation |
Dr. McDougal (MGH) Dr. Mueller (MGH) Dr. McGovern (MGH) |
Impotence:
|
1. Phase III trial of Viagra vs. longer acting drugs |
Provide a longer acting, more conveniently administered drug |
Viagra vs. New Drug |
Dr. Gomery (MGH) 617-726-8482 |
Kidney Stones:
|
1. Renagel/kidney stone prevention |
Reduce CaPs CaOX stone in recurrent stone forms |
Renagel in patients with high urine phosphase vs. high urine oxalate |
Dr. Curhan (MGH) 617-724-4633 |